<DOC>
	<DOCNO>NCT01605513</DOCNO>
	<brief_summary>The purpose study determine whether PEG-IFN-SA safe , tolerant effective treatment HCV patient .</brief_summary>
	<brief_title>Safety Study Recombinant Interferon Variant ( PEG-IFN-SA ) Treat HCV Disease</brief_title>
	<detailed_description>Chronic infection hepatitis C virus ( HCV ) significant public health problem china . Progressive liver disease , result chronic HCV infection , usually develop slowly 20-50 year may lead cirrhosis , hepatocellular carcinoma , liver failure eventual death . Symptoms typically mild non-specific nevertheless cause decrease quality life . Peginterferon alfa ribavirin combination therapy currently use china treatment chronic HCV . Successful treatment consider attainment sustain virological response ( SVR ) , define undetectable serum HCV ribonucleic acid ( RNA ) 6 month cessation treatment . PEG-IFN-SA new recombinant interferon variant . Its N-terminus modify 20KD molecular weight single-methoxy polyethylene glycol ( PEG ) . It consist 171 amino acid modification . PEG-IFN-SA reorganization , unnatural existence new type interferon ( 171Arg126Asp171IFN ) modification . The safety , tolerance antiviral activity PEG-IFN-SA test adult HCV infection . PEG-IFN-SA inject subcutaneously one time per week 12 time . Peginterferon alfa-2a ( Pegasys ) positive control drug . 80 patient randomly assign eight group ( PEG-IFN-SA 1.0μg/kg , Peginterferon alfa-2a 180 μg , PEG-IFN-SA 1.5 μg/kg，PEG-IFN-SA 2 μg/kg， PEG-IFN-SA 3 μg/kg，PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group，Intergen 15μg/48hours 7 time ribavirin 0.45g/bid 10 time ) . Clinical biological adverse effect record every week headache , nausea vomiting . HCV RNA level test COBAS Taqman HCV Test system Roche . Blood cell count test use automatic cell counter WBC , neutrophil , PLT HGB . Biochemical indicator test automatic biochemical analysis instrument .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>1. enrol voluntarily , understand sign inform consent ; 2 . More 18 year less 65 year ; 3. body mass index ( BMI ) 18 26 ; 4. antiHCV antibody / HCV RNA positive , / evidence chronic hepatitis C ; 5 . HCV RNA level ≥ 2000IU/ml ( equal viral load ) ; 6 . Women 's urine pregnancy test negative , subject ( male subject ) willing pregnancy plan next 18 month . ( 7 ) ALT within 6 time upper limit normal 1. pregnant woman , lactate woman plan pregnant next 18 month . 2. mental disorder , include history mental illness ( especially history depression depressive tendency , epilepsy , etc . ) ; 3 . The patient receive interferon therapy within past six month response previous interferon therapy . 4 . The patient use strong immune regulator two week three month screen , adrenocorticotropic hormone , thymosin α1 , thymus 5 peptide . 5 . The patient use hepatotoxic drug 6 month screen , dapsone , erythromycin , fluconazole , ketoconazole , rifampin . 6. coinfection virus ( HAV , HBV , HEV , HIV , EBV , CMV ) . 7. patient history hepatocellular carcinoma ( HCC ) , may hepatocellular carcinoma evidence , image suspicious nodule , AFP abnormal ( AFP &gt; 200ng/mL ) . FibroScan value great equal F3 Screening 8. cause liver disease : chronic alcoholic hepatitis , druginduced hepatitis , autoimmune liver disease , nonalcoholic steatohepatitis . 9. autoimmune disease , include psoriasis , systemic lupus erythematosus , thrombocytopenic purpura , . 10. heart vascular system diseases , history myocarditis , hypertension , coronary heart disease , pathological arrhythmia , stroke . 11. endocrine system disease , include thyroid disease , diabetes , etc . 12. pulmonary disease , include invasive pulmonary disease , pneumonia , shortness breath . 13 . Eye disease , include retinopathy , retinopathy . 14. chronic infectious disease history ( history tuberculosis ) . 15. chronic kidney disease , serum creatinine level &gt; 1.5 time upper limit normal screening , renal insufficiency , renal anemia history . 16. anemia ( include thalassemia , sickle hemoglobin , anemia ) , hemophilia . 17. peptic ulcer control , colitis , pancreatitis others . 18. malignancy . 19. peripheral blood checking : white blood cell count &lt; 3 × 109 / L ; neutrophil count &lt; 1.5 x 109 / L ; platelet count &lt; 90 × 109 / L ; hemoglobin less normal reference limit . 20. serum total bilirubin &gt; 2 time normal maximum reference value ( ULN ) ; serum albumin &lt; 35g / L ; history decompensated cirrhosis evidence . 21. evidence drug addiction ( include excessive alcohol intake , average alcohol consumption : men &gt; 40g / day ; woman &gt; 20g / day , equivalent 50 degree white wine 100ml / day 50ml / day ) within one year screening . 22. serious history drug food allergy , especially towards test drug ( interferon , ribavirin ) . 23. plan accept organ transplant organ transplant . 24. participate clinical trial 3 month screen 25 . The researcher judge patient factor may influence experiment . ribavirin exclusion criterion : 1. woman Hgb &lt; 12g/dl men Hgb &lt; 13gdl screening . 2. anemia patient ( eg , thalassemia , spherocytosis hyperlipidemia , gastrointestinal bleed history ) suspect anemia patient . 3. patient history coronary artery disease patient cerebrovascular disease join study , hemoglobin decline 4g/dl ( may observe ribavirin treatment ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>recombinant interferon , tolerate , effective</keyword>
</DOC>